Pfizer Inc.’s industry-leading profit margins and disposal of non-drug businesses still haven’t closed the valuation gap with rival drugmakers. No wonder its chief executive officer is contemplating a full breakup.
Pfizer Inc., the world’s largest drugmaker, rose to its highest price in more than four years after Goldman Sachs Group Inc. analysts said the company may go beyond the divestiture plans it has already announced.
Teva Pharmaceutical Industries Ltd. will focus drug-development efforts under new Chief Executive Officer Jeremy Levin on respiratory and central nervous system illnesses as the company seeks to replace medicines set to lose patent protection in the next three years.
Johnson & Johnson , the drugmaker that won approval last week for the first new AIDS medicine since 2008, plans to introduce four drugs this year that may combine for annual sales of $9 billion, helping to offset product recalls and declining profit for medical devices.